Spinal muscular atrophy (SMA) is the leading genetic cause of death for infants. However you are impacted, we have information and resources to support your needs.
News Feed
Novartis Announces Lift of Partial Clinical Trial Hold, Plans to Initiate a New Study of Intrathecal Zolgensma in Older Patients with SMA
Novartis announced that the U.S. Food and Drug Administration (FDA) has determined that OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy ...
Data for Genentech’s Evrysdi Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies with Type 1 SMA
Data from Genentech, a member of the Roche Group, recently announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH ...
Cure SMA Convenes Working Group to Discuss Biomarkers for SMA
The advent of three approved SMN-upregulating therapeutics for spinal muscular atrophy has dramatically changed the natural history of the disease. There are, ...
Community Spotlight
Community Spotlight: Dr. Arthur Burghes
On the 25th anniversary of the SMA Researcher Meeting, we would like you to learn more about Dr. Burghes and his ...
Community Spotlight: Doug McCullough
Doug McCullough was raised on a dairy farm in Pennsylvania and now resides in Central New Jersey. He is a self-described ...
Community Spotlight: Chan Family
Ten-year-old Brady Chan from North Carolina has big goals that stem from his passion for video games. He is part of an e-gaming team, where his favorite games ...
Cure SMA is committed to local support.
Find resources or a treatment site in your area.
Since 1984, we’ve invested $82 million in the research that has made today’s breakthroughs possible. We advance a comprehensive research program, attacking SMA from all sides.
The Cure SMA Care Center Network
Local, evidenced-based care centers, designed to develop an evidence-based standard of care to improve the lives of all those affected by SMA.
